MX2018013143A - 6-aminopiridin-3-il tiazoles como moduladores de ror?t. - Google Patents

6-aminopiridin-3-il tiazoles como moduladores de ror?t.

Info

Publication number
MX2018013143A
MX2018013143A MX2018013143A MX2018013143A MX2018013143A MX 2018013143 A MX2018013143 A MX 2018013143A MX 2018013143 A MX2018013143 A MX 2018013143A MX 2018013143 A MX2018013143 A MX 2018013143A MX 2018013143 A MX2018013143 A MX 2018013143A
Authority
MX
Mexico
Prior art keywords
roryt
aminopyridin
thiazoles
modulators
syndrome
Prior art date
Application number
MX2018013143A
Other languages
English (en)
Inventor
Goldberg Steven
Mcclure Kelly
M Tanis Virginia
G Fennema Elizabeth
D Lebsack Alec
L Martin Connor
Venkatesan Hariharan
Xue Xiaohua
R Woods Craig
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018013143A publication Critical patent/MX2018013143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Image Processing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención comprende compuestos de la Fórmula (I) (ver fórmula) en donde A1, A2, A3, A4, A5, R1 y R2 se definen en la especificación; la invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad son artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de ROR?t en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la Fórmula I.
MX2018013143A 2016-04-27 2017-04-26 6-aminopiridin-3-il tiazoles como moduladores de ror?t. MX2018013143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328074P 2016-04-27 2016-04-27
PCT/US2017/029531 WO2017189661A1 (en) 2016-04-27 2017-04-26 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT

Publications (1)

Publication Number Publication Date
MX2018013143A true MX2018013143A (es) 2019-04-24

Family

ID=59215941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013143A MX2018013143A (es) 2016-04-27 2017-04-26 6-aminopiridin-3-il tiazoles como moduladores de ror?t.

Country Status (26)

Country Link
US (5) US10975068B2 (es)
EP (1) EP3448856B1 (es)
JP (1) JP6893218B2 (es)
KR (1) KR20180135962A (es)
CN (1) CN109415358B (es)
AR (1) AR108344A1 (es)
AU (1) AU2017255525A1 (es)
BR (1) BR112018071942A2 (es)
CA (1) CA3022318A1 (es)
CL (1) CL2018003044A1 (es)
CO (1) CO2018011633A2 (es)
CR (1) CR20180505A (es)
EA (1) EA036318B1 (es)
EC (1) ECSP18088146A (es)
ES (1) ES2906258T3 (es)
IL (1) IL262381A (es)
MA (1) MA44772A (es)
MX (1) MX2018013143A (es)
NI (1) NI201800109A (es)
PE (1) PE20190150A1 (es)
PH (1) PH12018502209A1 (es)
SG (1) SG11201809162XA (es)
SV (1) SV2018005772A (es)
TW (1) TW201803869A (es)
UY (1) UY37213A (es)
WO (1) WO2017189661A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
KR20210060367A (ko) 2018-03-12 2021-05-26 에스칼리에 바이오사이언시스, 비브이 스피로사이클릭 ror-감마 조절제
WO2019177996A1 (en) * 2018-03-12 2019-09-19 Escalier Biosciences B.V. Bicyclic ror-gamma modulators
CA3103770A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
CN112292373A (zh) * 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
PL367325A1 (en) 2001-04-16 2005-02-21 Tanabe Seiyaku Co, Ltd. Large conductance calcium-activated k channel opener
PL210475B1 (pl) 2001-08-13 2012-01-31 Janssen Pharmaceutica Nv Pochodna 2,4,5-tripodstawionego tiazolilu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
JP2005507932A (ja) 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
AU2006215567B2 (en) 2005-02-16 2011-05-12 Abbott Healthcare Products B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
JP2009524677A (ja) 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
ES2567183T3 (es) 2008-07-17 2016-04-20 Bayer Cropscience Ag Compuestos heterocíclicos como pesticidas
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
EP2477963A4 (en) 2009-09-18 2013-02-27 Zalicus Pharmaceuticals Ltd ARYLSULFON DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
US9492439B2 (en) 2010-03-11 2016-11-15 New York University Amido compounds as RORγt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
US9500649B2 (en) 2010-12-28 2016-11-22 Arkray, Inc. Analytical tool and method for determining a condition of an oral cavity
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
EP2753327A4 (en) 2011-09-09 2015-04-08 Univ New York AMIDO COMPOUNDS AS ROR-GAMMA-T MODULATORS AND USES THEREOF
CA2856946C (en) 2011-12-02 2016-08-02 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
MX2014014614A (es) * 2012-05-31 2015-02-12 Phenex Pharmaceuticals Ag Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano ror [gamma).
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
CN105555768B (zh) 2013-09-20 2018-10-16 百时美施贵宝公司 RORγ调节剂
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2015057200A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of rorϒt
AU2014359324B2 (en) 2013-12-05 2019-02-21 Lead Pharma Holding B.V. ROR gamma (RORy) modulators
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
TW201609634A (zh) 2014-01-06 2016-03-16 必治妥美雅史谷比公司 吡咯啶基碸類視色素相關孤兒受體γ（ＲＯＲγ）調節劑
WO2015103510A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Heterocyclic sulfone as ror-gamma modulators
CN106061947B (zh) 2014-01-06 2019-12-03 百时美施贵宝公司 环己基砜RORγ调节剂
TWI659019B (zh) 2014-02-28 2019-05-11 日商帝人製藥股份有限公司 吡唑醯胺衍生物
WO2015139619A1 (zh) * 2014-03-18 2015-09-24 北京韩美药品有限公司 作为RORγ调节剂的化合物
WO2015145371A1 (en) 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
CN103833672A (zh) 2014-03-28 2014-06-04 中国药科大学 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法
CA2961033A1 (en) 2014-09-11 2016-03-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9861618B2 (en) 2014-10-30 2018-01-09 Janssen Pharmaceutica Nv Thiazoles as modulators of RORγt
BR112017008852A2 (pt) * 2014-10-30 2018-01-16 Janssen Pharmaceutica N.V. tiazóis substituídos com amida como moduladores do roryt
JOP20200117A1 (ar) * 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020059651A (ja) 2016-12-26 2020-04-16 科研製薬株式会社 ピラゾール誘導体及びそれを含有する医薬
FR3065000A1 (fr) 2017-04-06 2018-10-12 Galderma Research & Development Derives pyrazoles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
CA3103770A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt

Also Published As

Publication number Publication date
CN109415358B (zh) 2022-04-05
US20210221804A1 (en) 2021-07-22
BR112018071942A2 (pt) 2019-02-05
CN109415358A (zh) 2019-03-01
CO2018011633A2 (es) 2018-11-13
PH12018502209A1 (en) 2019-10-28
AR108344A1 (es) 2018-08-08
MA44772A (fr) 2019-03-06
SV2018005772A (es) 2019-03-28
AU2017255525A1 (en) 2018-10-25
US20210198251A1 (en) 2021-07-01
CR20180505A (es) 2019-03-14
UY37213A (es) 2017-10-31
EA036318B1 (ru) 2020-10-26
EP3448856B1 (en) 2022-01-05
JP2019515924A (ja) 2019-06-13
KR20180135962A (ko) 2018-12-21
NI201800109A (es) 2019-02-18
EA201892438A1 (ru) 2019-04-30
JP6893218B2 (ja) 2021-06-23
US10975068B2 (en) 2021-04-13
CA3022318A1 (en) 2017-11-02
IL262381A (en) 2018-11-29
US20230123208A1 (en) 2023-04-20
EP3448856A1 (en) 2019-03-06
PE20190150A1 (es) 2019-01-22
ES2906258T3 (es) 2022-04-13
US20170313691A1 (en) 2017-11-02
TW201803869A (zh) 2018-02-01
US20210188836A1 (en) 2021-06-24
WO2017189661A1 (en) 2017-11-02
CL2018003044A1 (es) 2019-02-01
ECSP18088146A (es) 2018-11-30
SG11201809162XA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2018013143A (es) 6-aminopiridin-3-il tiazoles como moduladores de ror?t.
PH12017502105A1 (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyT
MX358508B (es) Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
MX2016014294A (es) Composiciones y metodos para modular la expresion del factor b del complemento.
BR112017008842A2 (pt) tiazóis como moduladores de ror?t
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX2020007369A (es) Moduladores de la expresion de dnm2.
BR112016008257A2 (pt) moduladores de roryt de álcool quinolínico secundário